You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
鉅子生物(02367.HK)中期淨利潤9.8億元 同比增長47.2%
格隆匯 08-19 19:38

格隆匯8月19日丨鉅子生物(02367.HK)公吿,截至2024年6月30日止6個月的中期業績,收入25.4億元人民幣,同比增長58.2%;淨利潤9.8億元人民幣,同比增長47.2%;每股基本盈利0.99元。

總收入增長的主要原因是報吿期內公司持續擴充產品類型,深耕線上和線下渠道、打造明星單品並加強營銷,使得產品和品牌影響力進一步提升,銷售收入實現較快增長。

公司致力於將技術從實驗室帶入生活,成為中國美麗與健康領域的領先企業。報吿期內,世界權威市場調研機構歐睿國際發佈聲明,認定公司為"全球重組膠原蛋白領導者",進一步夯實了本公司在全球重組膠原蛋白領域的領先地位。

2024年上半年,外部環境依然充滿挑戰,公司按照既定規劃,開展新技術和產品的研發申報工作,推出重磅新品完善佈局,加大企業和品牌的宣傳營銷力度,拓展渠道觸點並持續優化全渠道運營能力,不忘初心,砥礪前行,為消費者帶去更多美好體驗,為行業健康發展貢獻力量。

展望2024下半年,公司將繼續投入研發,進一步豐富原料儲備和產品佈局,繼續做好三類醫療器械的臨牀申報工作。公司將以新產品、新系列為抓手,做好場景運營,拓展人羣資產,充分挖掘各平台增長機會,為品牌的中長期均衡成長打好基礎。公司將加大對企業品牌的打造,加大對旗下品牌營銷的投入力度,全域多觸點佔領消費者心智,傳播好公司的價值主張。公司希望和各位同業一道,共同創造中國成分和國貨美粧品牌的精彩未來。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account